The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results , with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35 billion, close to ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The ...

None of the 13 patients with bile duct involvement treated with inebilizumab flares experienced a flare compared with 12 of 15 on placebo, while neither of the two patients with l ...

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics.

Amgen announced that the US Food and Drug Administration (FDA) has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

Uplizna reduced the risk of IgG4-RD flare by 87%, with 10.3% of patients on Uplizna experiencing a flare versus 59.7% on placebo. 58.8% of Uplizna patients achieved flare-free, corticosteroid-free ...

Amgen’s Uplizna (inebilizumab-cdon) has been approved by the US Food and Drug Administration (FDA) as the first treatment for adults with immunoglobulin G4-related disease (IgG4-RD), a rare ...